Hoffmann-la Roche
Clinical trials sponsored by Hoffmann-la Roche, explained in plain language.
-
New MS drug trial for kids: could it slow the disease?
Disease control Not yet recruitingThis study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug moves through the body, if it is safe, and how it affects the immune system. Participants will receive the drug as a sh…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
New hope for kids with Crohn's: drug trial targets gut inflammation
Disease control Not yet recruitingThis study tests a new medicine called afimkibart in 100 children aged 2 to 17 with moderate to severe Crohn's disease. The goal is to see if the drug can safely reduce gut inflammation and bring symptoms under control. Participants will receive either the drug or a placebo, and …
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New hope for Hard-to-Treat breast cancer: Brain-Penetrating drug tested
Disease control Not yet recruitingThis study tests a new drug, RO7771950, designed to reach the brain, combined with standard therapies (trastuzumab and capecitabine) for people with advanced HER2-positive breast cancer that has spread or cannot be removed. It compares this new combo to another drug combo (tucati…
Phase: PHASE2, PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC